摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-苄氧基丙酸甲酯 | 4126-60-7

中文名称
3-苄氧基丙酸甲酯
中文别名
3-(苄氧基)丙酸甲酯
英文名称
methyl 3-(benzyloxy)propanoate
英文别名
3-Benzyloxy-propionsaeure-methylester;methyl 3-phenylmethoxypropanoate
3-苄氧基丙酸甲酯化学式
CAS
4126-60-7
化学式
C11H14O3
mdl
——
分子量
194.23
InChiKey
PLLAGNDLRNXFLU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    14
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2918990090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302
  • 储存条件:
    室温且干燥

SDS

SDS:ebc8466f8d514f020d9df78cdfbe12dd
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-苄氧基丙酸甲酯sodium ethanolate溶剂黄146 作用下, 以 乙醇 为溶剂, 反应 5.5h, 生成 5-methyl-2-{2-[(phenylmethyl)oxy]ethyl}[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
    参考文献:
    名称:
    Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential
    摘要:
    Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance. In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. The X-ray structure of PfDHODH was used to inform the medicinal chemistry program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite. This compound has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmaco-kinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance. These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compound toward clinical candidate status.
    DOI:
    10.1021/jm200592f
  • 作为产物:
    描述:
    3-苄氧基-1-丙醇bismuth(III) nitrate碲化氢 、 5%-palladium/activated carbon 作用下, 以 甲醇 为溶剂, 50.0 ℃ 、101.33 kPa 条件下, 反应 12.0h, 以75%的产率得到3-苄氧基丙酸甲酯
    参考文献:
    名称:
    Conversion of alcohols to alkyl esters and carboxylic acids using heterogeneous palladium-based catalysts
    摘要:
    揭示了从有机醇合成酯或羧酸的方法。为了形成酯,需要在氧气气氛中将醇与甲醇或乙醇反应。该反应在存在包括钯和一种共催化剂(包括铋、碲、铅、铈、钛、锌和/或铌,最好至少包括铋和碲)的催化剂的情况下发生。或者,该催化剂也可用于在反应混合物中添加水时从该醇中生成酸。
    公开号:
    US09593064B2
点击查看最新优质反应信息

文献信息

  • A Highly Convergent Approach toward (−)-Brevenal
    作者:Michael T. Crimmins、Mariam Shamszad、Anita E. Mattson
    DOI:10.1021/ol1008203
    日期:2010.6.4
    Construction of the AB-ring and E-ring cyclic ether fragments was achieved through asymmetric alkylation/ring-closing metathesis strategies. A Horner−Wadsworth−Emmons olefination was used in a key bond-forming step to couple the advanced cyclic fragments and enable rapid access to the AB-E ring system.
    报告了向高度收敛、不对称合成 brevenal 的进展。AB 环和 E 环环醚片段的构建是通过不对称烷基化/闭环复分解策略实现的。Horner-Wadsworth-Emmons 烯化用于关键的键形成步骤,以耦合高级环状片段并能够快速进入 AB-E 环系统。
  • Pyrazole derivatives
    申请人:Edwards John Paul
    公开号:US20050054707A1
    公开(公告)日:2005-03-10
    This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R 1 to R 4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    本发明涉及式(I)的吡唑衍生物或其药用可接受的盐、溶剂化合物或衍生物,其中R1至R4在描述中有定义,以及其制备方法、用于制备它们的中间体、含有它们的组合物以及这些衍生物的用途。本发明的化合物结合到酶逆转录酶,并且是调节剂,特别是其抑制剂。因此,本发明的化合物在治疗各种疾病中有用,包括那些与逆转录酶抑制有关的疾病。感兴趣的疾病包括由人类免疫缺陷病毒(HIV)和与之遗传相关的逆转录病毒引起的疾病,例如获得性免疫缺陷综合征(AIDS)。
  • [EN] TREX1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TREX1 ET LEURS UTILISATIONS
    申请人:TEMPEST THERAPEUTICS INC
    公开号:WO2021263079A1
    公开(公告)日:2021-12-30
    Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 ("TREX1").
    本文描述了化合物、制备这种化合物的方法、包含这种化合物的药物组合物和药物,以及利用这种化合物抑制三端修复外切酶1("TREX1")的方法。
  • Rhodium-Catalyzed Oxygenative Addition to Terminal Alkynes for the Synthesis of Esters, Amides, and Carboxylic Acids
    作者:Insu Kim、Chulbom Lee
    DOI:10.1002/anie.201303669
    日期:2013.9.16
    A gem of a couple: The title reaction of terminal alkynes with O and N nucleophiles proceeds in the presence of [Rh(cod)Cl}2], P(4‐FC6H4)3, and 4‐picoline N‐oxide. Alcohols, amines, and water add to the terminal alkynes to give esters, amides, and carboxylic acids, respectively. The reaction involves formation of a rhodium vinylidene, oxidation to a ketene by oxygen transfer, and nucleophilic addition
    一对夫妇的宝石:与O和N亲核试剂在[的Rh(COD)氯}存在所得末端炔烃的标题反应2 ],P(4-FC 6 H ^ 4)3,和4-甲基吡啶ñ -氧化物。醇,胺和水加到末端炔烃中,分别得到酯,酰胺和羧酸。该反应包括形成亚乙烯基铑,通过氧转移氧化成烯酮,以及亲核加成。
  • Efficient three-step sequence for the deamination of α-aminoesters. Application to the synthesis of CysLT1 antagonists
    作者:Alfredo González、Daniel Pérez、Carles Puig、Hamish Ryder、Jordi Sanahuja、Laia Solé、Jordi Bach
    DOI:10.1016/j.tetlet.2009.03.118
    日期:2009.6
    and efficient three-step sequence for the deamination of α-aminoesters is reported. This method is based on the NaBH4-mediated selective reduction of α-diazoesters to α-hydrazonoesters and has been successfully applied to the deamination of several representative α-aminoesters including some l-cysteine ethyl ester derivatives, key intermediates in the synthesis of a series of CysLT1 antagonists.
    报道了一种用于α-氨基酯的脱氨的实用且有效的三步顺序。该方法基于NaBH 4介导的将α-重氮酸酯选择性还原为α-肼基酸酯的方法,已成功应用于多种代表性的α-氨基酯的脱氨反应,包括一些1-半胱氨酸乙酯衍生物,这是合成α-半胱氨酸的关键中间体。 CysLT1拮抗剂系列。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐